Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study.

van Elst LT, Valerius G, Büchert M, Thiel T, Rüsch N, Bubl E, Hennig J, Ebert D, Olbrich HM.

Biol Psychiatry. 2005 Nov 1;58(9):724-30. Epub 2005 Jul 14.

PMID:
16018980
2.

Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study.

Olbrich HM, Valerius G, Rüsch N, Buchert M, Thiel T, Hennig J, Ebert D, Van Elst LT.

World J Biol Psychiatry. 2008;9(1):59-63.

PMID:
17853298
3.

An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients.

Stanley JA, Williamson PC, Drost DJ, Rylett RJ, Carr TJ, Malla A, Thompson RT.

Schizophr Bull. 1996;22(4):597-609.

4.

Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.

Ohrmann P, Siegmund A, Suslow T, Pedersen A, Spitzberg K, Kersting A, Rothermundt M, Arolt V, Heindel W, Pfleiderer B.

J Psychiatr Res. 2007 Oct;41(8):625-34. Epub 2006 Sep 1.

PMID:
16949099
5.

Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy.

Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, Canaran G, Rylett RJ, Neufeld RW.

Arch Gen Psychiatry. 1997 Oct;54(10):959-65.

PMID:
9337777
6.
7.

Altered prefrontal glutamate-glutamine-gamma-aminobutyric acid levels and relation to low cognitive performance and depressive symptoms in type 1 diabetes mellitus.

Lyoo IK, Yoon SJ, Musen G, Simonson DC, Weinger K, Bolo N, Ryan CM, Kim JE, Renshaw PF, Jacobson AM.

Arch Gen Psychiatry. 2009 Aug;66(8):878-87. doi: 10.1001/archgenpsychiatry.2009.86.

PMID:
19652127
8.

Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy.

Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC.

Arch Gen Psychiatry. 2007 Feb;64(2):193-200.

PMID:
17283286
9.

Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy.

Hasler G, Neumeister A, van der Veen JW, Tumonis T, Bain EE, Shen J, Drevets WC, Charney DS.

Biol Psychiatry. 2005 Dec 15;58(12):969-73. Epub 2005 Jul 25.

PMID:
16043137
10.

Abnormal excitatory neurotransmitter metabolism in schizophrenic brains.

Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT.

Arch Gen Psychiatry. 1995 Oct;52(10):829-36.

PMID:
7575102
11.

Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy.

Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X, Gil R, Slifstein M, Abi-Dargham A, Lisanby SH, Shungu DC.

Arch Gen Psychiatry. 2012 May;69(5):449-59. doi: 10.1001/archgenpsychiatry.2011.1519. Epub 2012 Jan 2.

PMID:
22213769
12.

The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia.

Bertolino A, Knable MB, Saunders RC, Callicott JH, Kolachana B, Mattay VS, Bachevalier J, Frank JA, Egan M, Weinberger DR.

Biol Psychiatry. 1999 Mar 15;45(6):660-7.

PMID:
10187995
13.

Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex.

Michael N, Erfurth A, Ohrmann P, Gössling M, Arolt V, Heindel W, Pfleiderer B.

Psychopharmacology (Berl). 2003 Jul;168(3):344-6. Epub 2003 Apr 9.

PMID:
12684737
14.

The glutamatergic system and its relation to the clinical effect of therapeutic-sleep deprivation in depression - an MR spectroscopy study.

Murck H, Schubert MI, Schmid D, Schüssler P, Steiger A, Auer DP.

J Psychiatr Res. 2009 Jan;43(3):175-80. doi: 10.1016/j.jpsychires.2008.04.009. Epub 2008 Jun 3.

PMID:
18533184
15.

Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.

Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, Mattay VS, Bertolino A, Hyde TM, Shannon-Weickert C, Akil M, Crook J, Vakkalanka RK, Balkissoon R, Gibbs RA, Kleinman JE, Weinberger DR.

Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12604-9. Epub 2004 Aug 13.

16.

Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study.

Ohrmann P, Siegmund A, Suslow T, Spitzberg K, Kersting A, Arolt V, Heindel W, Pfleiderer B.

Schizophr Res. 2005 Mar 1;73(2-3):153-7.

PMID:
15653258
17.

Regarding "Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study".

Théberge J, Jensen JE, Rowland LM.

Biol Psychiatry. 2007 May 15;61(10):1218-9; author reply 1219-20. Epub 2006 Sep 1. No abstract available.

PMID:
16950227
18.

What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update.

Abbott C, Bustillo J.

Curr Opin Psychiatry. 2006 Mar;19(2):135-9. Review.

PMID:
16612192
19.

Reduced cingulate glutamate/glutamine-to-creatine ratios in adult patients with attention deficit/hyperactivity disorder -- a magnet resonance spectroscopy study.

Perlov E, Philipsen A, Hesslinger B, Buechert M, Ahrendts J, Feige B, Bubl E, Hennig J, Ebert D, Tebartz van Elst L.

J Psychiatr Res. 2007 Dec;41(11):934-41. Epub 2007 Feb 15.

PMID:
17303167
20.

An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy.

Stanley JA, Williamson PC, Drost DJ, Carr TJ, Rylett RJ, Malla A, Thompson RT.

Arch Gen Psychiatry. 1995 May;52(5):399-406. Erratum in: Arch Gen Psychiatry 1995 Oct;52(10):799.

PMID:
7726721
Items per page

Supplemental Content

Write to the Help Desk